Anonymous ID: 543c40 Sept. 12, 2021, 8:19 a.m. No.14564770   ๐Ÿ—„๏ธ.is ๐Ÿ”—kun

>>14564748

Sorry, newfag here. Synopsis:

Conclusions:

Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

 

Ivermectin prophylaxis versus no ivermectin prophylaxis

Three studies involving 738 participants evaluated ivermectin for COVID-19 prophylaxis among health care workers and COVID-19 contacts. Meta-analysis of these 3 trials, assessing 738 participants, found that ivermectin prophylaxis among health care workers and COVID-19 contacts probably reduces the risk of COVID-19 infection by an average of 86% (79%โ€“91%) (3 trials, 738 participants; aRR 0.14, 95% CI 0.09โ€“0.21; 5.0% vs. 29.6% contracted COVID-19, respectively; low-certainty evidence; downgraded due to study design limitations and few included trials) (Figure โ€‹(Figure15).15). In 2 trials involving 538 participants, no severe adverse events were recorded (SoF Table โ€‹Table44).